Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

NCT07073183 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous NSCLC

Interventions

BIOLOGICAL: CV09070101 mRNA vaccine (CVHNLC) 50 µg
BIOLOGICAL: CV09070101 mRNA vaccine (CVHNLC) 100 µg
BIOLOGICAL: CV09070101 mRNA vaccine (CVHNLC) 200 µg
BIOLOGICAL: CV09070101 mRNA vaccine (CVHNLC) 400 µg
BIOLOGICAL: CV09070101 mRNA vaccine (CVHNLC) 400 µg

Sponsor

CureVac